aspartic acid has been researched along with pd 184352 in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brunet, JP; Fisher, DE; Golub, TR; Jalili, A; Lupien, M; Mertz, KD; Pashenkov, M; Pathria, G; Ramaswamy, S; Stingl, G; Wagner, C; Wagner, SN; Widlund, HR | 1 |
1 other study(ies) available for aspartic acid and pd 184352
| Article | Year |
|---|---|
Dual suppression of the cyclin-dependent kinase inhibitors CDKN2C and CDKN1A in human melanoma.
Topics: Animals; Antineoplastic Agents; Aspartic Acid; Benzamides; Blotting, Western; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p18; Cyclin-Dependent Kinase Inhibitor p21; Flow Cytometry; Gene Expression Regulation, Neoplastic; Genes, ras; Glutamic Acid; Glycine; Humans; MAP Kinase Signaling System; Melanocytes; Melanoma; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-jun; RNA, Small Interfering; Transcription Factor AP-1; Transfection; Transplantation, Heterologous; Valine; Viral Vaccines | 2012 |